Interestingly, two recent mouse studies confirmed an advantage in controlling tumor cell growth when using SHP-2 inhibitors in combination with anti-PD-1/PD-L1 therapy (Zhao et al., 2019; Chen et al., 2020). Here, PTPN11 is linked to neoplasm.